---
annotation-target: fonc-11-651494.pdf
---


>%%
>```annotation-json
>{"created":"2022-08-08T06:06:24.389Z","updated":"2022-08-08T06:06:24.389Z","document":{"title":"Determining the Appropriate Treatment for T-Cell Acute Lymphoblastic Leukemia With SET-CAN/NUP214 Fusion: Perspectives From a Case Report and Literature Review","link":[{"href":"urn:x-pdf:2fef2038058f8988b22e09ab45457e1c"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-651494.pdf"}],"documentFingerprint":"2fef2038058f8988b22e09ab45457e1c"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-651494.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-651494.pdf","selector":[{"type":"TextPositionSelector","start":10145,"end":10181},{"type":"TextQuoteSelector","exact":" Chest CT showed an enlarged thymus.","prefix":"higher than 30% were listed. (E)","suffix":" (F) Survival analysis of all 38"}]}]}
>```
>%%
>*%%PREFIX%%higher than 30% were listed. (E)%%HIGHLIGHT%% ==Chest CT showed an enlarged thymus.== %%POSTFIX%%(F) Survival analysis of all 38*
>%%LINK%%[[#^700ydq5p2iq|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^700ydq5p2iq


>%%
>```annotation-json
>{"created":"2022-08-08T06:09:30.614Z","updated":"2022-08-08T06:09:30.614Z","document":{"title":"Determining the Appropriate Treatment for T-Cell Acute Lymphoblastic Leukemia With SET-CAN/NUP214 Fusion: Perspectives From a Case Report and Literature Review","link":[{"href":"urn:x-pdf:2fef2038058f8988b22e09ab45457e1c"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-651494.pdf"}],"documentFingerprint":"2fef2038058f8988b22e09ab45457e1c"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-651494.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-651494.pdf","selector":[{"type":"TextPositionSelector","start":12553,"end":12792},{"type":"TextQuoteSelector","exact":"carfilzomib has been shown in previous studies to have anantileukemic role in T-cell leukemia cell lines (28, 29).Unfortunately, carfilzomib is still clinically unavailable inChina, and thus, our patient did not receive carfilzomib therapy","prefix":" selective proteasome inhibitor,","suffix":".We further analyzed the surviva"}]}]}
>```
>%%
>*%%PREFIX%%selective proteasome inhibitor,%%HIGHLIGHT%% ==carfilzomib has been shown in previous studies to have anantileukemic role in T-cell leukemia cell lines (28, 29).Unfortunately, carfilzomib is still clinically unavailable inChina, and thus, our patient did not receive carfilzomib therapy== %%POSTFIX%%.We further analyzed the surviva*
>%%LINK%%[[#^eewmt8cczyd|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^eewmt8cczyd
